title: Effect of (E)-2-(3,4-dimethoxyphenyl)-4-oxo-4H-chromen-7-yl-3-(3,4-dimethoxyphenyl) acrylate on the development of atopic dermatitis-like lesions.
abstract: OBJECTIVE
  In this study, we synthesized a novel chemical, (E)-2-(3,4-dimethoxyphenyl)-4-oxo-4H-chromen-7-yl-3-(3,4-dimethoxyphenyl) acrylate (CSH) and investigated the effect of CSH on atopic dermatitis (AD) by evaluating the anti-inflammatory effect of CSH on immune cells in vitro and on atopic dermatitis-like lesions in vivo.
  
  
  METHODS
  Human monocytic THP-1 cells and human eosinophilic EoL-1 cells were treated with house dust mite extract in the absence and presence of CSH. Nc/Nga mice were sensitized to 2,4-dinitrochlorobenzne (DNCB) for 5 weeks and then orally and dorsally administered with CSH or dexamethasone for 3 weeks.
  
  
  RESULTS
  CSH inhibited the secretion of monocyte chemotactic protein-1 (MCP-1), interleukin (IL)-6 and IL-8 due to house dust mite extract in THP-1 cells. CSH also suppressed the secretion of MCP-1 and IL-8 in EoL-1 cells. In vivo, the skin severity score decreased after CSH treatment as compared to the control group. CSH suppressed the inflammatory cell infiltration into the dermis and thickened the epidermis. CSH reduced serum IgE level as compared to the control group. The levels of IL-4, IL-5, IL-13 and eotaxin in mouse splenocytes increased after treatment with concanavalin A and the increase of the cytokines was decreased by pre-treatment with CSH. The inhibitory effects of CSH on atopic lesions of DNCB-treated Nc/Nga mice were similar to those of dexamethasone, despite differing degrees depending on results evaluated in this study.
  
  
  CONCLUSIONS
  These results may contribute to the development of a therapeutic drug for the treatment of AD.
authors.affiliation: Department of Biomedical Laboratory Science, School of Medicine, Eulji University, Daejeon 301-746, Republic of Korea.
authors.forename: In Sik
authors.initials: IS
authors.lastname: Kim
authors.forename: Gyu-Yong
authors.initials: GY
authors.lastname: Song
authors.forename: Dong-Hee
authors.initials: DH
authors.lastname: Kim
authors.forename: Soo Hyun
authors.initials: SH
authors.lastname: Cho
authors.forename: Chi-Young
authors.initials: CY
authors.lastname: Yun
authors.forename: Ji-Sook
authors.initials: JS
authors.lastname: Lee
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002460:Cell Line; D018932:Chemokine CCL2 / Q000276:immunology / Q000378:metabolism; D003208:Concanavalin A / Q000633:toxicity; D003373:Coumaric Acids / Q000008:administration & dosage / Q000494:pharmacology*; D003374:Coumarins / Q000008:administration & dosage / Q000494:pharmacology*; D016207:Cytokines / Q000276:immunology / Q000378:metabolism; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D003907:Dexamethasone / Q000008:administration & dosage / Q000494:pharmacology; D004195:Disease Models, Animal; D004804:Eosinophils / Q000187:drug effects* / Q000276:immunology; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D015850:Interleukin-6 / Q000276:immunology / Q000378:metabolism; D016209:Interleukin-8 / Q000276:immunology / Q000378:metabolism; D051379:Mice; D009000:Monocytes / Q000187:drug effects* / Q000276:immunology; D039981:Pyroglyphidae / Q000276:immunology; D012720:Severity of Illness Index; D013154:Spleen / Q000166:cytology / Q000187:drug effects
chemical_list: C576266:2-(3,4-dimethoxyphenyl)-4-oxo-4H-chromen-7-yl 3-(3,4-dimethoxyphenyl)acrylate; D000893:Anti-Inflammatory Agents; D018932:Chemokine CCL2; D003373:Coumaric Acids; D003374:Coumarins; D016207:Cytokines; D015850:Interleukin-6; D016209:Interleukin-8; D003208:Concanavalin A; D007073:Immunoglobulin E; D003907:Dexamethasone